Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 1.00 |
| ▸ | HTR1A | P08908 | 9/20 | 1.00 |
| ▸ | HTR6 | P50406 | 9/20 | 1.00 |
| ▸ | HTR2C | P28335 | 9/20 | 1.00 |
| ▸ | HTR2B | P41595 | 8/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 7/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 7/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 7/20 | 1.00 |
| ▸ | HRH1 | P35367 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 7/20 | 1.00 |
| ▸ | HTR1D | P28221 | 7/20 | 1.00 |
| ▸ | HTR1E | P28566 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 6/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31498037 | 0.92 | HTR1A (0.84) | HTR2AHTR1AHTR6HTR2CHTR2B | |
| SCHEMBL24243748 | 0.92 | HTR1A (0.84) | HTR2AHTR1AHTR6HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL30413582 | 0.90 | HTR1A (0.82) | HTR2AHTR1AHTR6HTR2CHTR2B | |
| SCHEMBL24243770 | 0.90 | HTR2A (0.82) | HTR2AHTR1AHTR6HTR2CHTR2B | |
| SCHEMBL31498058 | 0.90 | HTR2A (0.82) | HTR2AHTR1AHTR6HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL30413017 | 0.89 | HTR2A (0.80) | HTR2AHTR1AHTR6HTR2CHTR2B | |
| SCHEMBL18085051 | 0.89 | HTR1A (0.80) | HTR2AHTR1AHTR6HTR2CHTR2B | |
| SCHEMBL18085058 | 0.87 | HTR1A (0.76) | HTR2AHTR1AHTR6HTR2CHTR2B | |
| SCHEMBL23042907 | 0.85 | HTR2A (0.74) | HTR2AHTR1AHTR6HTR2CHTR2B | |
| SCHEMBL30183299 | 0.85 | HTR2A (0.74) | HTR2AHTR1AHTR6HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| EP-4247340-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | Bexson Biomedical, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| US-11534454-B2 | Complexing agent salt formulations of pharmaceutical compounds | BEXSON BIOMEDICAL, INC. (US) | 2022-12-27 | — | — | US | claimed |
| WO-2022109050-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2022-05-26 | — | — | US | claimed |
| US-20220152088-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. | 2022-05-19 | — | — | US | claimed |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | disclosed |
| EP-4704806-A1 | INJECTABLE PHARMACEUTICAL FORMULATIONS | Cybin IRL Limited (IE) | 2026-03-11 | — | — | EP | disclosed |
| US-20260053831-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | DIAMOND THERAPEUTICS INC (CA) | 2026-02-26 | — | — | US | disclosed |
| US-20200345585-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2020-11-05 | — | — | US | disclosed |
| EP-3713568-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-09-30 | — | — | EP | disclosed |
| EP-0763032-B1 | PALLADIUM CATALYZED RING CLOSURE OF TRIAZOLYL TRYPTAMINE | MERCK & CO INC (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-0925302-B1 | PALLADIUM CATALYZED INDOLIZATION | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-5808064-A | HYDROSILATION OF AN INDOLE AS CHEMICAL INTERMEDIATE | MERCK & CO., INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5567824-A | CATALYZING THE CYCLIZATION IN PRESENCE OF A SOLVENT AND A PROTON ACCEPTOR | MERCK & CO., INC. (US) | 1996-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | BDNF, NTRK2, GRIN2A | HTR2A 33/4885HTR1A 34/4885HTR6 68/4885 |
| US-20200345585-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | SLC38A7, QPCT, SLC18A3 | HTR2A 2029/4885HTR1A 1984/4885HTR6 1812/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR2A 14/4885HTR1A 9/4885HTR6 15/4885 |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 11/4885HTR1A 13/4885HTR6 2/4885 |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | QPCT, SLC38A7, QPCTL | HTR2A 2610/4885HTR1A 2572/4885HTR6 2030/4885 |
| US-20220152088-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | SLC10A1, SLC5A6, MC2R | HTR2A 2775/4885HTR1A 2998/4885HTR6 1130/4885 |
| US-11534454-B2 | Complexing agent salt formulations of pharmaceutical compounds | SLC10A1, SLC5A6, MC2R | HTR2A 2775/4885HTR1A 2998/4885HTR6 1130/4885 |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 9/4885HTR1A 11/4885HTR6 2/4885 |
| US-20260053831-A1 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | HTR1B, HTR2B, HTR3B | HTR2A 9/4885HTR1A 7/4885HTR6 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.